Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
Portfolio Pulse from Lara Goldstein
COMPASS Pathways plc (NASDAQ:CMPS) has shared results from its research on the potential of its AI technologies to support its proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD). The AI model could predict results up to 12 weeks post-treatment. The model reportedly yielded a cross-validated accuracy of 85% and 88% at the three- and twelve-week timepoints, respectively.
September 06, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
COMPASS Pathways' AI model could potentially enhance the effectiveness of its psilocybin treatment for TRD, which could positively impact the company's stock.
The successful application of AI in predicting the results of COMPASS Pathways' psilocybin treatment for TRD could lead to increased investor confidence in the company's innovative approach, potentially driving up the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100